Seamus Fernandez
Stock Analyst at Guggenheim
(4.37)
# 367
Out of 4,918 analysts
103
Total ratings
52.7%
Success rate
19.17%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $936 → $942 | $755.19 | +24.74% | 17 | Jul 11, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $36.83 | +214.96% | 8 | Jul 2, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $50 → $68 | $63.37 | +7.31% | 4 | Jun 24, 2025 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $17 | $7.98 | +113.03% | 1 | Jun 24, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $13.48 | +226.41% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $14.29 | - | 3 | Apr 3, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $33.32 | +380.19% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $32.38 | +72.95% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $13.93 | - | 2 | Feb 24, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $130 → $122 | $78.64 | +55.14% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $37.36 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $86.75 | -19.31% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.20 | +158.06% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.02 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.61 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $11.89 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $17.64 | +183.45% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $43.74 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.00 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $114.20 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.15 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.54 | +3,417.92% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $21.75 | +106.90% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $73.61 | -48.38% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $23.32 | +62.95% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Jul 11, 2025
Maintains: Buy
Price Target: $936 → $942
Current: $755.19
Upside: +24.74%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $36.83
Upside: +214.96%
Cidara Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $50 → $68
Current: $63.37
Upside: +7.31%
Amylyx Pharmaceuticals
Jun 24, 2025
Initiates: Buy
Price Target: $17
Current: $7.98
Upside: +113.03%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $13.48
Upside: +226.41%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.29
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $33.32
Upside: +380.19%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $32.38
Upside: +72.95%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.93
Upside: -
Merck & Co.
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $78.64
Upside: +55.14%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $37.36
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $86.75
Upside: -19.31%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $6.20
Upside: +158.06%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.02
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.61
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $11.89
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $17.64
Upside: +183.45%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $43.74
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.00
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $114.20
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.15
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.54
Upside: +3,417.92%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $21.75
Upside: +106.90%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $73.61
Upside: -48.38%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $23.32
Upside: +62.95%